Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism

Journal of Neurology

Volumn 258, Issue 12, 2011, Pages 2230-2239

  Van Den Bogaard, Simon J A ^a   Dumas, Eve M ^a   Teeuwisse, Wouter M ^a   Kan, Hermien E ^a   Webb, Andrew ^a   Roos, Raymund A C ^a   Jeroen Van Der Grond, ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Energy metabolism; Huntington's disease; MRI; MRS

Indexed keywords

CHOLINE; CREATINE; GLUTAMIC ACID; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN LEVEL; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENERGY METABOLISM; EXCITOTOXICITY; FEMALE; FRONTAL LOBE; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS; MALE; METABOLIC DISORDER; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PUTAMEN; THALAMUS;

ADULT; BRAIN; ENERGY METABOLISM; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 83255186677     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6099-5     Document Type: Article

References (35)

1. Aylward EH, Anderson NB, Bylsma FW, Wagster MV, Barta PE, Sherr M, Feeney J, Davis A, Rosenblatt A, Pearlson GD, Ross CA (1998) Frontal lobe volume in patients with Huntington's disease. Neurology 50:252-258
2. Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA (2004) Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63:66-72 (Pubitemid 38943780)
3. Aziz NA, Pijl H, Frolich M, van der Graaf AW, Roelfsema F, Roos RA (2009) Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J Clin Endocrinol Metab 94:1223-1228
4. Beck AT, Steer RA, Brown GK (1996) BDI-II, Beck Depression Inventory: Manual, 2nd edn. Harcourt Brace, San Antonio
5. Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF (2008) Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 58(1):209-225
6. Clarke CE, Lowry M, Quarrell OWJ (1998) No change in striatal glutamate in Huntington's disease measured by proton magnetic resonance spectroscopy. Parkinsonism Relat Disord 4(3):123-127 (Pubitemid 29031446)
7. Dunlop DS, Mc Hale DM, Lajtha A (1992) Decreased brain N-acetylaspartate in Huntington's disease. Brain Res 580:44-48
8. Estrada Sanchez AM, Mejia-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 39:265-276 (Pubitemid 351221151)
9. Gomez-Anson B, Alegret M, Munoz E, Sainz A, Monte GC, Tolosa E (2007) Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology 68:906-910 (Pubitemid 46584537)
10. Gujar SK, Maheshwari S, Bjorkman-Burtscher I, Sundgren PC (2005) Magnetic resonance spectroscopy. J Neuroophthalmol 25:217-226 (Pubitemid 41306683)
11. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43:2689-2695 (Pubitemid 24004570)
12. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, Mac- Donald M, Rosen BR, Beal MF, Koroshetz WJ (1998) 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 50:1357-1365 (Pubitemid 28240352)
13. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004) A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65:267-277 (Pubitemid 38443548)
14. Mekle R, Mlynarik V, Gambarota G, Hergt M, Krueger G, Gruetter R (2009) MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 61:1279-1285
15. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, McDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2007) Detection of Huntington's disease decades before diagnosis: the predict HD study. J Neurol Neurosurg Psychiatry 79(8):874-880
16. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41:689-692 (Pubitemid 27212666)
17. Perneger TV (1998) What's wrong with Bonferroni adjustments. BMJ 316:1236-1238 (Pubitemid 28171344)
18. Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P (2008) Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 131:2860-2869
19. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672-679 (Pubitemid 23360802)
20. Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14:260-264 (Pubitemid 32611437)
21. Reynolds NC Jr, Prost RW, Mark LP (2005) Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 1031:82-89 (Pubitemid 40038366)
22. Roos RAC (1986) Neuropathology of Huntington's chorea. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of clinical neurology, extrapyramidal disorders. Elsevier Science Publishers, Amsterdam
23. Roze E, Saudou F, Caboche J (2008) Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 21:497-503
24. Ruocco HH, Lopes-Cendes I, Li LM, Cendes F (2007) Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Mov Disord 22:2052-2056
25. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio AA, Viano J, de Yebenes JG (1999) Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 53:806-812 (Pubitemid 29448304)
26. Schmand B, Bakker D, Saan R, Louman J (1991) The Dutch reading test for adults: a measure of premorbid intelligence level. Tijdschr Gerontol Geriatr 22:15-19
27. Sturrock A, Laule C, Decolongon J, Dar SR, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, MacKay AL, Leavitt BR (2010) Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 75(19):1702-1710
28. Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT (2003) Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 61:141-142 (Pubitemid 36818771)
29. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations ofHuntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791-801
30. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791-801
31. Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE, Brooks DJ (1996) Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 11:167-173 (Pubitemid 26082784)
32. Taylor-Robinson SD, Weeks RA, Sargentoni J, Marcus CD, Bryant DJ, Harding AE, Brooks DJ (1994) Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet 343:1170
33. Tkac I, Oz G, Adriany G, Ugurbil K, Gruetter R (2009) In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 62:868-879
34. van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA (2010) Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol 258(3):412-420
35. van Oostrom JC, Sijens PE, Roos RA, Leenders KL (2007) 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res 1168:67-71 (Pubitemid 47320622)